Myocardial contrast echocardiography a 25-year retrospective

Sanjiv Kaul

doi:10.1161/CIRCULATIONAHA.107.747303

Myocardial contrast echocardiography a 25-year retrospective

Sanjiv Kaul

Research output: Contribution to journal › Review article › peer-review

98 Scopus citations

Abstract

It is remarkable that there is already a vast literature, including large studies, showing the diagnostic and prognostic value of MCE even before a single ultrasound contrast agent has been approved in the United States for this purpose. The response of the US Food and Drug Administration to phase III study results of Cardiosphere and Imagify and subsequent reimbursement for MCE will determine its clinical adoption and success. Whether MCE develops into a universally applied clinical tool or not, it has been a valuable experimental tool for the discovery of new physiological and pathophysiological insights into the microcirculation and local control of MBF. Some of these have been described previously and some in this review. For a relatively inexpensive tool, MCE can provide rather sophisticated information in individual patients in various clinical scenarios. Its greater clinical adoption can only enhance patient care.

Original language	English (US)
Pages (from-to)	291-308
Number of pages	18
Journal	Circulation
Volume	118
Issue number	3
DOIs	https://doi.org/10.1161/CIRCULATIONAHA.107.747303
State	Published - Jul 15 2008

Keywords

Contrast media
Coronary disease
Echocardiography
Imaging

ASJC Scopus subject areas

Cardiology and Cardiovascular Medicine
Physiology (medical)

Access to Document

10.1161/CIRCULATIONAHA.107.747303

Cite this

@article{c05e0fb8a3e1461eb23d97f75fa119b0,

title = "Myocardial contrast echocardiography a 25-year retrospective",

abstract = "It is remarkable that there is already a vast literature, including large studies, showing the diagnostic and prognostic value of MCE even before a single ultrasound contrast agent has been approved in the United States for this purpose. The response of the US Food and Drug Administration to phase III study results of Cardiosphere and Imagify and subsequent reimbursement for MCE will determine its clinical adoption and success. Whether MCE develops into a universally applied clinical tool or not, it has been a valuable experimental tool for the discovery of new physiological and pathophysiological insights into the microcirculation and local control of MBF. Some of these have been described previously and some in this review. For a relatively inexpensive tool, MCE can provide rather sophisticated information in individual patients in various clinical scenarios. Its greater clinical adoption can only enhance patient care.",

keywords = "Contrast media, Coronary disease, Echocardiography, Imaging",

author = "Sanjiv Kaul",

year = "2008",

month = jul,

day = "15",

doi = "10.1161/CIRCULATIONAHA.107.747303",

language = "English (US)",

volume = "118",

pages = "291--308",

journal = "Circulation",

issn = "0009-7322",

publisher = "Lippincott Williams and Wilkins",

number = "3",

}

TY - JOUR

T1 - Myocardial contrast echocardiography a 25-year retrospective

AU - Kaul, Sanjiv

PY - 2008/7/15

Y1 - 2008/7/15

N2 - It is remarkable that there is already a vast literature, including large studies, showing the diagnostic and prognostic value of MCE even before a single ultrasound contrast agent has been approved in the United States for this purpose. The response of the US Food and Drug Administration to phase III study results of Cardiosphere and Imagify and subsequent reimbursement for MCE will determine its clinical adoption and success. Whether MCE develops into a universally applied clinical tool or not, it has been a valuable experimental tool for the discovery of new physiological and pathophysiological insights into the microcirculation and local control of MBF. Some of these have been described previously and some in this review. For a relatively inexpensive tool, MCE can provide rather sophisticated information in individual patients in various clinical scenarios. Its greater clinical adoption can only enhance patient care.

AB - It is remarkable that there is already a vast literature, including large studies, showing the diagnostic and prognostic value of MCE even before a single ultrasound contrast agent has been approved in the United States for this purpose. The response of the US Food and Drug Administration to phase III study results of Cardiosphere and Imagify and subsequent reimbursement for MCE will determine its clinical adoption and success. Whether MCE develops into a universally applied clinical tool or not, it has been a valuable experimental tool for the discovery of new physiological and pathophysiological insights into the microcirculation and local control of MBF. Some of these have been described previously and some in this review. For a relatively inexpensive tool, MCE can provide rather sophisticated information in individual patients in various clinical scenarios. Its greater clinical adoption can only enhance patient care.

KW - Contrast media

KW - Coronary disease

KW - Echocardiography

KW - Imaging

UR - http://www.scopus.com/inward/record.url?scp=49149094134&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=49149094134&partnerID=8YFLogxK

U2 - 10.1161/CIRCULATIONAHA.107.747303

DO - 10.1161/CIRCULATIONAHA.107.747303

M3 - Review article

C2 - 18625905

AN - SCOPUS:49149094134

SN - 0009-7322

VL - 118

SP - 291

EP - 308

JO - Circulation

JF - Circulation

IS - 3

ER -

Myocardial contrast echocardiography a 25-year retrospective

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this